Biomarkers of Alzheimer's disease pathophysiology and delirium

阿尔茨海默病病理生理学和谵妄的生物标志物

阅读:1

Abstract

BACKGROUND: Alzheimer's disease (AD) is characterised by amyloid-beta (A) and tau (T) pathology, and neurodegeneration (N). AT(N) neuropathology precedes the symptomatic presentation of the disease. This asymptomatic phase may present vulnerability towards delirium, but studies are inconclusive. In this cross-sectional study of hip fracture patients, we aimed to explore the association between AD biomarkers for AT(N) neuropathology and delirium, with focus on patients without clinical dementia. METHODS: The AT(N) biomarkers were analysed in cerebrospinal fluid (CSF) in hip fracture patients (n = 401). Pre-fracture dementia was defined by IQCODE ≥3.44 (n = 164). Delirium was diagnosed according to the DSM-5 criteria. The CSF concentrations of amyloid-beta(1-42) (Aβ42), amyloid-beta(1-40) (Aβ40), phosphorylated tau(181) (p-tau) and total-tau (t-tau) were quantified by Lumipulse G assays (Fujirebo, Ghent, Belgium). The Aβ42/Aβ40 ratio (cutoff A+ <0.72), p-tau(181) (T+ >50 pg/ml) and t-tau (N+ >409 pg/ml) were used to determine A, T and N status, respectively. FINDINGS: Hip fracture patients with delirium had lower CSF Aβ42 concentrations and higher concentrations of CSF p-tau and CSF t-tau than those without delirium (student's t-test, all p-values <0.001). Brain Aβ-deposition, A+ was more common in patients with delirium (χ(2) p < 0.001). In patients without pre-fracture dementia, delirium was associated with lower CSF Aβ42 concentrations (student's t-test, p = 0.005), and higher CSF concentrations of p-tau (student's t-test p = 0.004) and t-tau (student's t-test p = 0.002). A higher proportion developed delirium among those A+T+ (33%) compared to A-T- (17%, χ(2) p = 0.02). INTERPRETATION: These findings support that the AD AT neuropathology is a risk factor for delirium in patients without clinical dementia. FUNDING: South-Eastern Norway Regional Health Authorities (# 2017095), the Norwegian Health Association (#16149, #19536, #1513) and by Wellcome Leap's Dynamic Resilience Program (jointly funded by Temasek Trust) (#104617).

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。